about
Development of enteric-coated fixed dose combinations of amorphous solid dispersions of ezetimibe and lovastatin: Investigation of formulation and process parameters.Assessment of Passive Intestinal Permeability Using an Artificial Membrane Insert System.The artificial membrane insert system as predictive tool for formulation performance evaluation.Validation of Dissolution Testing with Biorelevant Media: An OrBiTo Study.The effect of 2-hydroxypropyl-β-cyclodextrin on the intestinal permeation through mucus.Gastrointestinal behavior of itraconazole in humans - Part 2: The effect of intraluminal dilution on the performance of a cyclodextrin-based solution.Synthesis and preclinical evaluation of [11C]MA-PB-1 for in vivo imaging of brain monoacylglycerol lipase (MAGL).
P50
Q36268362-066C1B76-8756-4D7B-AE06-FD806CBC8A6BQ38615743-F03CC90C-AD0D-43C9-8699-40257EB966EFQ47308587-31935258-CB10-471F-8AB5-9EED32BF5EE5Q48358292-B3F58C8F-46F9-45B9-BD7B-8E497E36CA0BQ49600973-19D63CC8-0FF2-4858-98E4-7C488E5BE59CQ50694981-066C25F7-462D-43B0-A929-670008588391Q52095822-3FB24CC8-09DD-41B1-89E4-04699915698A
P50
description
researcher
@en
wetenschapper
@nl
name
Philippe Berben
@en
Philippe Berben
@nl
type
label
Philippe Berben
@en
Philippe Berben
@nl
prefLabel
Philippe Berben
@en
Philippe Berben
@nl
P31
P496
0000-0002-4452-0871